Engineering proteins to control cell signaling in cancer
Engineering protein-specific proteases: targeting signaling proteins
['FUNDING_R01'] · UNIV OF MARYLAND, COLLEGE PARK · NIH-11041284
This study is working on creating special proteins that can help control certain signals in cancer cells, especially those related to the RAS family, with the hope of finding new ways to treat cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MARYLAND, COLLEGE PARK (nih funded) |
| Locations | 1 site (COLLEGE PARK, UNITED STATES) |
| Trial ID | NIH-11041284 on ClinicalTrials.gov |
What this research studies
This research focuses on developing specialized proteases that can specifically target and control signaling proteins involved in cancer, particularly the RAS family of proteins. The approach involves identifying key dynamic regions within these proteins and engineering proteases that can activate or inhibit their function. By using advanced techniques such as protein engineering, enzymology, and cell biology, the researchers aim to create tools that can modulate signaling pathways in human cell cultures, potentially leading to new cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with bladder cancer or those whose tumors are driven by RAS signaling mutations.
Not a fit: Patients with cancers not associated with RAS signaling or those who do not have active RAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that more effectively target cancer signaling pathways, improving treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in targeting RAS signaling pathways, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
COLLEGE PARK, UNITED STATES
- UNIV OF MARYLAND, COLLEGE PARK — COLLEGE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ORBAN, JOHN — UNIV OF MARYLAND, COLLEGE PARK
- Study coordinator: ORBAN, JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer, Cancer Model, Cancer cell line, CancerModel